Feature | HRS | May 16, 2017

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

HRS presentations include data on the S-ICD, Micra, Nanostim, PV isolation, lead extractions and pharma

An electrophysiology EP ablation procedure to treat a heart arrhythmia

May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 annual meeting May 10-13, in Chicago. The data presented is for the latest in electrophysiology (EP) clinical research, techniques and technologies. These trials were featured at Heart Rhythm 2017 and will be published in the July issue of the Heart Rhythm Journal. 

Late-breaking Studies Presented at HRS 2017:

• The S-ICD Post-market Approval Study

Intra-nasal Etripamil For Conversion Of Paroxysmal Supraventricular Tachycardia (PSVT). Node-1 Trial

A Leadless Pacemaker In The Real-world Setting: The Micra Transcatheter Pacing System Post-approval Registry

• EWOLUTION trial: 1-Year Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation

High Incidence Of Previously Unknown (“Silent”) Atrial Fibrillation In Patients At High Risk For Atrial Fibrillation And Stroke: Primary Results From The REVEAL AF Study

Compliant Endovascular Balloon Reduces the Lethality of Superior Vena Cava Tears During Transvenous Lead Extractions

First-in-man Feasibility Study Of Subcutaneous Defibrillation Utilizing An Integrated Flexible String Shaped Defibrillator

PV Isolation With A Novel Multielectrode Radiofrequency Balloon Catheter That Allows Directionally-tailored Energy Delivery (RADIANCE): A Multicenter First-in-man Experience

• A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU (Apixaban Evaluation Of Interrupted Or Uninterrupted Anticoagulation For Ablation Of Atrial Fibrillation) Trial

• Long Detection Programming In Single Chamber Defibrillators Reduces Unnecessary Therapies And Mortality: The Advance III Trial

• SPECT-guided Left Ventricular Lead Placement For Improved CRT Efficacy: A Randomized Controlled Trial

• Ranolazine in High-Risk ICD Patients (RAID) Trial

• Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment In Subjects With Recurrent Atrial Fibrillation: Results From The Powder AF Multicentre Randomised Trial

• The Nanostim Leadless Pacemaker: Battery Failures and Worldwide Chronic Device Retrieval

 

Other Key Presentations:

VIDEO: Editor's Choice of Most Innovative New Technology at HRS 2017

VIDEO: EP Lead Extraction Strategies, interview with Bruce Wilkoff, M.D.

VIDEO: Current State of Leadless Pacemaker Technology, interview with Vivek Reddy, M.D.

VIDEO: Overview of Subcutaneous ICD Technology

VIDEO: How to Start an Electrophysiology Program

Expert Consensus Released on Catheter, Surgical Ablation of Atrial Fibrillation

Expert Consensus on MRI and Radiation Exposure in Patients With Implantable Cardiac Electronic Devices

Watch the VIDEO "Current State of Atrial Fibrillation Technologies," an interview with Dr. Hugh Calkins.

Watch the VIDEO interview with HRS President Michael Gold, M.D., on latest EP technology trends

 

Link to Heart Rhythm 2018 Late-breaking Studies
 

For more information: www.hrssessions.org

Related Content

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...
Overlay Init